Medical Developments International Limited (MDDVF)
| Market Cap | 38.18M -27.4% |
| Revenue (ttm) | 27.11M +6.8% |
| Net Income | -290.82K |
| EPS | -0.00 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 56.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,500 |
| Open | 0.33446 |
| Previous Close | n/a |
| Day's Range | 0.33446 - 0.33446 |
| 52-Week Range | 0.3038 - 0.3707 |
| Beta | 1.41 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 21, 2026 |
About MDDVF
Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers Penthrox, a trauma and emergency pain relief product for use in hospitals, emergency departments, ambulance services, sport medicines, and for analgesia during short procedures. The company also distributes asthma and chronic obstructive pulmonary disease products, such space chambers, peak flow mete... [Read more]
News
Medical Developments International Earnings release: Q4 2026
Medical Developments International released its Q4 2026 earnings on July 23, 2026, summarizing the period's financial results.
Medical Developments International Earnings Call Transcript: H1 2026
Group revenue grew 8% year-over-year, led by 18% growth in pain management, while respiratory declined 10%. Underlying earnings and cash flow improved, with strong progress on pediatric approvals in Europe and margin initiatives. Second half earnings are expected to be lower due to seasonal respiratory softness.
Medical Developments International Quarterly report: H1 2026
Medical Developments International has published its H1 2026 quarterly earnings report on February 18, 2026.
Medical Developments International Slides: H1 2026
Medical Developments International has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 18, 2026.
Medical Developments International Earnings release: H1 2026
Medical Developments International released its H1 2026 earnings on February 18, 2026, summarizing the period's financial results.
Medical Developments International Earnings release: Q2 2026
Medical Developments International released its Q2 2026 earnings on January 9, 2026, summarizing the period's financial results.
Medical Developments International Transcript: AGM 2025
The AGM highlighted a strong financial turnaround in FY 2025, with revenue up 18% and positive cash flow. Board renewal was a focus, with new directors elected and a new Chair announced. Strategic priorities include accelerating Penthrox growth, expanding investments, and managing regulatory and market risks.
Medical Developments International Earnings release: Q1 2026
Medical Developments International released its Q1 2026 earnings on October 9, 2025, summarizing the period's financial results.
Medical Developments International Earnings Call Transcript: H2 2025
FY25 saw strong revenue and margin growth, with pain management up 23% and respiratory up 9%. Strategic initiatives, including new distribution partnerships and pediatric approval in Europe, set the stage for accelerated volume growth in FY26, despite expected near-term EBIT softness.
Medical Developments International Annual report: H2 2025
Medical Developments International has published its H2 2025 annual report on August 20, 2025.
Medical Developments International Annual report: H2 2025
Medical Developments International has published its H2 2025 annual report on August 20, 2025.
Medical Developments International Slides: H2 2025
Medical Developments International has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 20, 2025.
Medical Developments International Earnings release: H2 2025
Medical Developments International released its H2 2025 earnings on August 20, 2025, summarizing the period's financial results.